论文部分内容阅读
FDA于2008-09-30批准增加蛋白酶抑制剂阿扎那韦(atazanavir sulfate,Reyataz胶囊,由百时美施贵宝公司研发)的适应证,允许其与利托那韦联用治疗新确诊的HIV-1感染。其推荐给药剂量为:阿扎那韦300mg+利托
The FDA approved the addition of the atazanavir sulfate (Reyataz capsule, developed by Bristol-Myers Squibb) to its combination with ritonavir for the treatment of newly diagnosed HIV- 1 infection. The recommended dosage is: atazanavir 300mg + Rito